Cancer Immunotherapy Market Research 2024: The Race for the Cures - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer including Executive and Consultant Guides
13 mars 2024 11h26 HE
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya
12 mars 2024 11h01 HE
|
Intrommune Therapeutics
Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board.
Global Kaposi Sarcoma Market Analysis 2024-2034: HAART Emerges as a Game-Changer in HIV Treatment, Paving the Way for Control and Prevention of AIDS-Associated Kaposi Sarcoma
11 mars 2024 13h46 HE
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Kaposi Sarcoma Market by Type, by Treatment, by End-Users, and By Region" report has been added to ResearchAndMarkets.com's offering. The...
Interleukin-2 (IL-2) Inhibitor Drug Pipeline Research Report 2024
05 mars 2024 03h30 HE
|
Research and Markets
Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides...
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
27 févr. 2024 15h52 HE
|
BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
27 févr. 2024 07h00 HE
|
Purple Biotech Ltd.
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...
Turnstone Biologics to Participate in Upcoming Investor Conferences
21 févr. 2024 06h00 HE
|
Turnstone Biologics Corp.
Turnstone to present and participate in TD Cowen 44th Annual Global Health Care Conference and Leerink Partners Global Biopharma Conference 2024.
China Oncology Drugs Market Report, 2023 and 2024-2028 - Cancer Prevention Takes Center Stage in China's National Health Agenda
19 févr. 2024 07h48 HE
|
Research and Markets
Dublin, Feb. 19, 2024 (GLOBE NEWSWIRE) -- The "China Oncology Drugs Market, Size, Forecast 2024-2028, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been...
Vaccinex, Inc. Announces Reverse Stock Split
15 févr. 2024 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Allergy Immunotherapy Soars: Anticipating a $2.69 Billion Market by 2028 with an Impressive CAGR of 8.12%
05 févr. 2024 04h41 HE
|
Research and Markets
Dublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Allergy Immunotherapy Market (2023-2028) by Type, Application and Distribution Channel, and Geography, Competitive Analysis, Impact of Covid-19,...